Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 5
2005 5
2006 4
2007 3
2008 2
2009 4
2010 6
2011 7
2012 11
2013 5
2014 5
2015 14
2016 9
2017 14
2018 14
2019 8
2020 7
2021 9
2022 11
2023 10
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ohlmann c
Search for Ohlman C instead (1 results)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B; CheckMate 214 Investigators. Motzer RJ, et al. N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
Enzalutamide in metastatic prostate cancer before chemotherapy.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, Miller K, Noonberg SB, Perabo F, Phung D, Saad F, Scher HI, Taplin ME, Venner PM, Tombal B; PREVAIL Investigators. Beer TM, et al. N Engl J Med. 2014 Jul 31;371(5):424-33. doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1. N Engl J Med. 2014. PMID: 24881730 Free PMC article. Clinical Trial.
[Hormone-sensitive prostate cancer].
Ohlmann C. Ohlmann C. Urologie. 2023 Apr;62(4):345-346. doi: 10.1007/s00120-023-02054-z. Epub 2023 Apr 4. Urologie. 2023. PMID: 37014381 German. No abstract available.
Erstlinientherapie beim lokal fortgeschrittenen oder metastasierten Urothelkarzinom: Eine randomisierte, kontrollierte Phase-III-Studie zum Vergleich von Pembrolizumab mit und ohne platinbasierter Kombinations-Chemotherapie und der alleinigen Chemotherapie bei Patienten mit fortgeschrittenem oder metastasiertem Urothelkarzinom (Keynote-361) AB 54/16 der AUO.
Rexer H, Ohlmann CH, Retz M. Rexer H, et al. Among authors: ohlmann ch. Aktuelle Urol. 2018 Feb;49(1):21-22. doi: 10.1055/s-0043-125341. Epub 2018 Feb 1. Aktuelle Urol. 2018. PMID: 29390213 German. No abstract available.
Erstlinientherapie beim lokal fortgeschrittenen oder metastasierten Urothelkarzinom: Eine randomisierte, doppelblinde Phase-III-Multicenterstudie zur adjuvanten Nivolumab-Therapie versus Placebo bei Patienten mit invasivem Hochrisiko-Urothelkarzinom (CheckMate 274) – AB 58/17 der AUO.
Rexer H, Ohlmann CH, Gschwend J. Rexer H, et al. Among authors: ohlmann ch. Aktuelle Urol. 2018 Aug;49(4):308-309. doi: 10.1055/a-0633-7395. Epub 2018 Aug 7. Aktuelle Urol. 2018. PMID: 30086585 German. No abstract available.
[Multimodal treatment strategies for urologic cancers].
Bolenz C, Kübler H, Ohlmann C. Bolenz C, et al. Among authors: ohlmann c. Urologie. 2022 Dec;61(12):1313-1314. doi: 10.1007/s00120-022-01969-3. Epub 2022 Dec 7. Urologie. 2022. PMID: 36477913 German. No abstract available.
[Role of local treatments in prostate cancer].
Ohlmann CH, Grimm MO. Ohlmann CH, et al. Urologie. 2024 Mar;63(3):213-214. doi: 10.1007/s00120-024-02286-7. Epub 2024 Mar 6. Urologie. 2024. PMID: 38446156 German. No abstract available.
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, Leroy S, Durieu I, Weiss L, Grenet D, Stremler N, Ohlmann C, Reix P, Porzio M, Roux Claude P, Rémus N, Douvry B, Montcouquiol S, Cosson L, Mankikian J, Languepin J, Houdouin V, Le Clainche L, Guillaumot A, Pouradier D, Tissot A, Priou P, Mély L, Chedevergne F, Lebourgeois M, Lebihan J, Martin C, Zavala F, Da Silva J, Lemonnier L, Kelly-Aubert M, Golec A, Foucaud P, Marguet C, Edelman A, Hinzpeter A, de Carli P, Girodon E, Sermet-Gaudelus I, Pranke I; French CF Reference Network study group. Dreano E, et al. Among authors: ohlmann c. Eur Respir J. 2023 Oct 19;62(4):2300110. doi: 10.1183/13993003.00110-2023. Print 2023 Oct. Eur Respir J. 2023. PMID: 37696564
[Bone metastases].
Ohlmann CH. Ohlmann CH. Aktuelle Urol. 2013 Mar;44(2):141-9. doi: 10.1055/s-0032-1324997. Epub 2013 Apr 11. Aktuelle Urol. 2013. PMID: 23580385 German.
Is there an anti-androgen withdrawal syndrome for enzalutamide?
von Klot CA, Kramer MW, Böker A, Herrmann TR, Peters I, Kuczyk MA, Ligges U, Gschwend JE, Retz M, Schmid SC, Stenzl A, Schwentner C, Todenhöfer T, Stöckle M, Ohlmann CH, Azone I, Mager R, Bartsch G, Haferkamp A, Heidenreich A, Piper C, Merseburger AS. von Klot CA, et al. Among authors: ohlmann ch. World J Urol. 2014 Oct;32(5):1171-6. doi: 10.1007/s00345-014-1288-3. Epub 2014 Apr 2. World J Urol. 2014. PMID: 24691670
139 results